The effective components of Flavomycin premix is Flavophospholipol, which is a phosphorus-containing glycolipid. It is added in feed for growth promoting and prevention to some diseases. Meanwhile, it is not used as therapeutic drugs of human being or animal. Therefore it is approved to use as an antibiotic feed additive around the world. Effectivity ● To improve animal health and productivity, meanwhile, no adverse effect on the proliferation of probiotics. ● To increase nutritive digestion and absorption because of decreasing the thickness of animal intestine ● To increase the sensitivity of harmful bacteria to medicine because of inhibiting the transfer of resistant plasmid ● To protect animal, human being and environment because of decreasing the duration and prevalence of harmful bacteria (Salmonella and clostridium etc.) ● To keep microorganism group of ruminant rumen to good conditions and improve fibrin digestion. Stability ● Flavomycin premix has a good stability in mixing with other nutritive of feed, even at the conditions of mixing with liquefied feed and acidified feed, high temperature (90-110℃) ect. Safety ● No harm to animal, human being and environment ● No withdrawal time and drug residues ● No cross-resistance with other antibiotics ● Inhibiting transfer of resistant plasmid
Growth Promoting

CAS NO:11015-37-5

EC NO:234-246-7

Molecular Formula:C₆₉H₁₀₇N₄O₃₅P

Molecular Weight:1583.5674

Synonyms:;Flavomycin;(2R)-3-{[{[(2R,3R,4R,5S,6S)-3-{[(2S,3R,4R,5S,6R)-3-(acetylamino)-5-{[(2S,3R,4R,5S,6R)-3-(acetylamino)-4-hydroxy-6-methyl-5-({(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)carbamoyl]tetrahydro-2H-pyran-2-yl}oxy)tetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-({[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}methyl)tetrahydro-2H-pyran-2-yl]oxy}-6-carbamoyl-4-(carbamoyloxy)-5-hydroxy-5-methyltetrahydro-2H-pyran-2-yl]oxy}(hydroxy)phosphoryl]oxy}-2-{[(2Z,6E,13E)-3,8,8,14,18-pentamethyl-11-methylidenenonadeca-2,6,13,17-tetraen-1-yl]oxy}propanoic acid (non-preferred name);(2S,3S,4R,5R,6R)-5-{[(2S,3R,4R,5S,6R)-3-(acetylamino)-5-{[(2S,3R,4R,5S,6R)-3-(acetylamino)-4-hydroxy-6-methyl-5-({(2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-[(2-hydroxy-5-oxocyclopent-1-en-1-yl)carbamoyl]tetrahydro-2H-pyran-2-yl}oxy)tetrahydro-2H-pyran-2-yl]oxy}-4-hydroxy-6-({[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}methyl)tetrahydro-2H-pyran-2-yl]oxy}-4-(carbamoyloxy)-6-({[(2R)-2-carboxy-2-{[(2E,6E,13E)-3,8,8,14,18-pentamethyl-11-methylidenenonadeca-2,6,13,17-tetraen-1-yl]oxy}ethoxy](hydroxy)phosphoryl}oxy)-3-hydroxy-3-methyltetrahydro-2H-pyran-2-carboxylic acid (non-preferred name);

Molecular Structure: